You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

fibroblast growth factor receptor (FGFR)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)

Recruiting
  • Advanced or Recurrent Solid Tumors
  • FGFR Gene Alterations
  • Aoba-ku, Sendai, Miyagi, Japan
  • +4 more
May 9, 2022

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))

Completed
  • Advanced or Metastatic Solid Tumor
  • Rogaratinib (BAY1163877)
  • Copanlisib (BAY80-6946)
  • Los Angeles, California
  • +19 more
Jul 13, 2022

Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

Terminated
Has Results
  • Bladder Cancer
  • Indianapolis, Indiana
  • +2 more
Jul 7, 2022

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Intrahepatic Cholangiocarcinoma Trial (Famitinib)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • (no location specified)
Jun 16, 2021

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)

Withdrawn
  • Bladder Transitional Cell Carcinoma
  • +2 more
  • (no location specified)
Aug 8, 2022

Urinary Bladder Tumors, Receptors, Fibroblast Growth Factor Trial in Japan (Erdafitinib Intravesical Delivery System)

Not yet recruiting
  • Urinary Bladder Neoplasms
  • Receptors, Fibroblast Growth Factor
  • Erdafitinib Intravesical Delivery System
  • Kanagawa, Japan
  • +3 more
Jan 27, 2023

Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))

Terminated
  • Solid Tumours
  • Debio1347 (CH5183284)
  • Boston, Massachusetts
  • +7 more
Sep 8, 2020

Serum Fibroblast Growth Factor-21 Levels During Prolonged

Completed
  • Fibroblast Growth Factor-21
  • Fasting
  • 12 hour fasting for 29 days
  • Ankara, Turkey
    Hacettepe University Nutrition and Dietetics Department
Mar 29, 2023

Squamous-Cell Non-Small-Cell Lung Cancer Trial in Worldwide (Bemarituzumab, Docetaxel)

Recruiting
  • Squamous-Cell Non-Small-Cell Lung Cancer
  • Orange, California
  • +24 more
Jul 27, 2022

Tumors Trial in Worldwide (Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib

Completed
Has Results
  • Neoplasms
  • Rogaratinib (BAY1163877) oral solution
  • +2 more
  • Chicago, Illinois
  • +28 more
Apr 12, 2021

Solid Tumors Trial (Bemarituzumab)

Recruiting
  • Solid Tumors
  • Duarte, California
  • +54 more
Feb 1, 2023

Fibroblast Growth Factor 21, Tast Perference Trial (Fibroblast growth factor 21 infusion, Placebo infusion (saline))

Active, not recruiting
  • Fibroblast Growth Factor 21
  • Tast Perference
  • Fibroblast growth factor 21 infusion
  • Placebo infusion (saline)
  • Hellerup, Denmark
    Amalie R Lanng
Nov 21, 2022

Fibrous Dysplasia Of Bone Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (Burosumab)

Not yet recruiting
  • Fibrous Dysplasia Of Bone
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))

Completed
  • Carcinoma, Hepatocellular
  • JNJ-42756493 (erdafitinib)
  • Changchun, China
  • +9 more
Feb 17, 2020

Fibroblast Growth Factor 23 and Sclerostin in Relation to

Not yet recruiting
  • COVID-19
  • Calcium
  • +3 more
  • Aswan, Egypt
    Aswan University hospital
Mar 11, 2022

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

NAFLD Trial in Ahvaz (Soy isoflavone, Placebo)

Completed
  • NAFLD
  • Soy isoflavone
  • Placebo
  • Ahvaz, Khuzestan, Iran, Islamic Republic of
    Asal Neshatbini Tehrani
Oct 24, 2023

Healthy Trial in Frederiksberg (Sucrose, Sucrose + protein, Sucrose + fat)

Completed
  • Healthy
  • Sucrose
  • +2 more
  • Frederiksberg, Denmark
    Department of Nutrition, Exercise and Sports, University of Cope
Mar 30, 2022